Relationships between TT virus infection and hepatitis C virus response to interferon therapy in doubly infected patients

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 176-182

  Maggi, Fabrizio ^a   Fornai, C ^a   Tempestini, A ^a   Andreoli, E ^a   Lanini, L ^a   Vatteroni, M L ^a   Pistello, M ^a   Marchi, S ^a   Antonelli, G ^b   Bendinelli, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Genogroups; HCV; Interferon; Response to therapy; TTV; Viral load

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PREVALENCE; SUPERINFECTION; TORQUE TENO VIRUS; VIREMIA; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS C VIRUS; RNA VIRUSES; TT VIRUS;

EID: 12444346413     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bendinelli M, Vatteroni ML, Maggi F, Pistello M. Hepatitis C virus, biology, pathogenesis, epidemiology, clinical description, and diagnosis. In: Specter S, ed. Viral hepatitis: diagnosis, therapy, and prevention. Totowa, NJ: Humana Press, 1999; 65-127.
2. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36 (Suppl.): S135-44.
3. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36 (Suppl.): S114-20.
4. Barnes E, Webster G, Whalley S, Dusheiko G. Predictors of a favourable response to alpha interferon therapy for hepatitis C. Clin Liver Dis 1999; 3: 775-91.
5. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999; 1: 237-43.
6. Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1998; 29: 214-23.
7. Hayashi K, Fukuda Y, Nakano I, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000; 6: 677-81.
8. Weltman MD, Brotodihardijo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.
9. Yu ML, Chuang WL, Dai CY, et al. GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-alpha therapy. Antiviral Res 2001; 52: 241-9.
10. Bendinelli M, Pistello M, Maggi F, Fornai C, Freer G, Vatteroni ML. Molecular properties, biology and clinical implications of TT virus, a recently identified widespread infectious agent of humans. Clin Microbiol Rev 2001; 14: 98-113.
11. Maggi F, Pistello M, Vatteroni ML, et al. Dynamics of persistent TT virus infection, as estimated in patients treated with interferon-alpha for concomitant hepatitis C. J Virol 2001; 75: 11999-2004.
12. Pistello M, Morrica A, Maggi F, et al. TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathologies. J Med Virol 2001; 63: 189-95.
13. Maggi F, Pifferi M, Fornai C, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol 2003; 77: 2418-25.
14. Saback FL, Gomes SA, Niel C. High frequency of mixed TT virus infections in healthy adults and children detected by a simplified heteroduplex mobility assay. J Virol Meth 2002; 101: 117-25.
15. Maggi F, Fornai C, Morrica A, et al. High prevalence of TT virus viremia in Italian patients regardless of age, clinical diagnosis, and previous interferon treatment. J Infect Dis 1999; 180: 838-42.
16. Peng YH, Nishizawa T, Takahashi M, Ishikawa T, Yoshikawa A, Okamoto H. Analysis of the entire genomes of thirteen TT virus variants classifiable into the fourth and fifth genetic groups, isolated from viremic infants. Arch Virol 2002; 147: 21-41.
17. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
18. Akahane Y, Sakamoto M, Miyazaki Y et al. Effect of interferon on a nonenveloped DNA virus (TT virus) associated with acute and chronic hepatitis of unknown etiology. J Med Virol 1999; 58: 196-200.
19. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
20. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antiviral Ther 2000; 5: 85-90.
21. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9: 340-5.
22. Brouwer TB, Hansen BE, Niesters HGM, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-8.
23. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1647-53.
24. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-56.
25. Antonelli G, Riva E, Maggi F, Vatteroni ML, Simeoni E. Influence of HCV genotype, HCV RNA load and ALT level on reduction of HCV RNA after a single administration of interferon alpha. J Infect Dis 1999; 180: 1411-2.
26. Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of typed-I interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-7.
27. Kato N, Yoshida H, Kioko Ono-Nita S, et al. Activation of intracellular signalling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000; 32: 405-12.
28. Okamoto H, Ukita M; Nishizawa T, et al. Circular double-stranded forms of TT virus DNA in the liver. J Virol 2000; 74: 5161-7.
29. Asabe S, Nishizawa T, Iwanari H, Okamoto H. Phosphorylation of serine-rich protein encoded by open reading frame 3 of the TT virus genome. Biochem Biophys Res Commun 2001; 286: 298-304.
30. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signalling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001; 288: 379-90.
31. O'Brien PM, Saveria Campo M. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 2002; 88: 103-17.
32. Haig DM, Thomson J, McInnes C, et al. Orf virus immuno-modulation and the host immune response. Vet Immunol Immunopathol 2002; 87: 395-9.